Accessibility StatementSkip Navigation SAN FRANCISCO, Oct. 24, 2025 /PRNewswire/ -- A new class action complaint has been filed against aTyr Pharma, Inc. (NASDAQ: ATYR) and certain of its top executives, significantly enlarging the alleged class period covered by the ongoing securities litigation. aTyr Pharma, Inc. (AYTR) Securities Litigation: The suits allege that aTyr and its top executives made false and misleading statements about the efficacy of its drug, Efzofitimod, leading investors to purchase sto ...

BENSALEM, Pa., Oct. 24, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against aTyr Pharma Inc. ("aTyr" or the "Company") (NASDAQ:Â ATYR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of ...

Accessibility StatementSkip Navigation NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. ("aTyr" or the "Company") (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of aTyr investors who were adversely affected by alleged securities fraud between January 16, 2025 and September 12, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] As detailed be ...

MIAMI, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Shamis & Gentile, P.A. announces that it has filed a class action complaint for violations of the federal securities laws against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) and a senior executive of the Company. The case is pending in the U.S. District Court for the Southern District of California and is captioned King v. aTyr Pharma, Inc., No. 25-cv-02826 (the “King Action”). The King Action is related to the class action an investor ...

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

诉讼核心信息 - Levi & Korsinsky律师事务所通知aTyr Pharma Inc (NASDAQ: ATYR)的投资者有关集体诉讼证券诉讼 [1] - 诉讼旨在为在2025年1月16日至2025年9月12日期间因涉嫌证券欺诈而遭受损失的投资者挽回损失 [1] 诉讼案件细节 - 指控被告向投资者提供了过于积极的陈述 同时传播虚假和误导性陈述及/或隐瞒有关Efzofitimod疗效的重大不利事实 特别是该药物使患者能够完全停止使用类固醇的能力 [2] - 真相于2025年9月15日（盘前）揭露 aTyr在一次投资者电话会议中宣布EFZO-FIT研究未达到其主要终点 [2] - 具体而言 公司宣布该研究在第48周时未达到从基线开始的平均每日OSC剂量变化的主要终点 [2] - 鉴于令人失望的顶线结果 aTyr宣布下一步将与FDA沟通以确定前进路径 [2] - 此消息公布后 aTyr普通股股价从2025年9月12日的收盘价每股6.03美元下跌至2025年9月15日的每股1.02美元 单日内跌幅达83.2% [2] 律师事务所信息 - Levi & Korsinsky律师事务所在过去20年间为受损股东追回数亿美元资金 并在高风险案件中拥有胜诉记录 [4] - 该律所在复杂证券诉讼中代表投资者方面拥有广泛专业知识 拥有超过70名员工的团队为客户服务 [4] - 连续七年 Levi & Korsinsky被ISS Securities Class Action Services评为美国顶级证券诉讼律所之一 [4]

公司事件 - Pomerantz LLP宣布对aTyr Pharma Inc提起集体诉讼，指控公司及其部分高管可能涉及证券欺诈或其他非法商业行为 [1][2] - 诉讼相关投资者需在2025年12月8日前申请成为首席原告 [2] - 诉讼背景源于aTyr于2025年9月15日公布其Efzofitimod治疗肺结节病的EFZO-FIT三期研究未达到主要终点 [4] 临床研发进展 - aTyr的关键三期EFZO-FIT研究是一项随机、双盲、安慰剂对照试验，旨在评估静脉注射Efzofitimod在肺结节病患者中的安全性和有效性 [4] - 该研究的主要终点是第48周时平均每日口服糖皮质激素剂量相较于基线的变化，但结果未达到此主要终点 [4] - 鉴于令人失望的顶线结果，公司下一步计划与美国食品药品管理局沟通以确定后续发展路径 [4] 市场反应 - 三期研究失败的消息导致aTyr股价在2025年9月15日暴跌每股5.01美元，跌幅达83.17%，收盘报每股1.01美元 [5]

Accessibility StatementSkip Navigation CONTACT: The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected]Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? NEW YORK, Oct. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lea ...

公司概况与诉讼背景 - aTyr Pharma Inc 是一家临床阶段生物技术公司 专注于将tRNA合成酶生物学转化为治疗纤维化和炎症的新疗法 [1] - 针对该公司的一项集体诉讼已被提起 诉讼代表在2025年1月16日至2025年9月12日期间购买公司普通股的投资者 [1] - 诉讼指控公司就其候选药物的疗效误导投资者 [1] 指控核心内容 - 指控称 公司高管在介绍其EFZO-FIT三期研究时 对研究设计中的强制减量方法表示信心 但隐瞒了该药物允许患者完全停止使用类固醇的能力 [2] - 该研究是一项针对肺结节病患者的随机、双盲、安慰剂对照研究 旨在评估Efzofitimod静脉制剂的安全性和有效性 [2] 关键事件与市场影响 - 2025年9月15日 公司宣布EFZO-FIT研究未达到其主要终点 即第48周时平均每日口服糖皮质激素剂量相对于基线的变化 [3] - 此消息导致公司普通股股价从2025年9月12日的收盘价每股6.03美元 暴跌至2025年9月15日的每股1.02美元 单日跌幅达83.2% [3] - 公司宣布下一步将与FDA沟通 以确定后续发展路径 [3]